IPK in the News

Institut Pasteur Korea "We will help the rapid drug discovery with the Phenomic Technologies"

2017-02-01

“In the race to find the next first-in-class drug, being able to quickly move along the drug discovery process can potentially save time, money and lives,” said David Shum, Team Leader of Assay Development and Screening, Institut Pasteur Korea(IPK).

IPK announces that the institute offers its ‘Phenomic Technologies’ and services that accelerate research programs focused on the discovery of first-in-class drug candidates to the domestic/international institutes and organizations.

For over a decade, IPK’s ‘Phenomic Technologies’ and services have been employed by many distinguished international and Korean organizations. ‘Phenomic Technologies’ was employed in the discovery of Q203, a novel compound highly effective against both multi-drug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis (TB) currently being tested as a first-in-class drug candidate by the US FDA and identifying a Thiophene Urea (TU) compound series that has the potential to be a first-in-class hepatitis C virus drug candidate.

-Source: Maeil Economy (February 1, 2017)
-Image source: Institut Pasteur Korea

LIST